June 22, 2020
Diabetes is one of the leading causes of disability and death in the United States. One in 10 Americans have diabetes – more than 30 million people – and another 84 million adults are at high risk of developing Type 2 diabetes.1 Furthermore, the latest figures show that the obesity rate in the United States has reached 42.4%.2 Interventions to impact these conditions have traditionally been ineffective. Approaches like chronic care management (CCM) are recognized by CMS for reducing costs and improving outcomes to address chronic conditions, including Type 2 diabetes and obesity. Nonalcoholic fatty liver disease (NALFD) and nonalcoholic steatohepatitis (NASH) are highly prevalent in people living with metabolic syndrome (MetS) and are recognized not only as leading causes of liver disease, but also contributors to increased cardiovascular disease (CVD) mortality among people living with Type 2 diabetes. MetaPhy and Echosens are collaborating to develop CCM programs that are more accessible and effective for clinicians, especially gastroenterologists, who are at the forefront of managing NAFLD and NASH.
Download your copy of the white paper below.